Postprandial control of gallbladder contraction and exocrine pancreatic secretion in man
- PMID: 1282465
- DOI: 10.1111/j.1365-2362.1992.tb01453.x
Postprandial control of gallbladder contraction and exocrine pancreatic secretion in man
Abstract
To explore the interactions between cholecystokinin (CCK) and the cholinergic system, we compared the effect of cholinergic or peptidergic CCK blockade on gallbladder contraction and pancreatic enzyme secretion using atropine and loxiglumide (a specific CCK antagonist) as pharmacological tools. Gallbladder contraction was measured by sonography and pancreatic secretion by a marker perfusion and aspiration technique. Graded doses of exogenous CCK8 induced dose-dependent contractions of the gallbladder and increasing enzyme outputs. Loxiglumide (10 mg kg-1 h-1) abolished the gallbladder response and prevented an increase in pancreatic enzyme secretion to CCK8. Atropine (5 micrograms kg-1 h-1), however, only reduced gallbladder contraction and enzyme output to CCK8. Gallbladder volumes decreased maximally to 12 +/- 4% after oral food, whereas enzyme output and plasma CCK levels increased 6- to 8-fold. Loxiglumide completely abolished gallbladder contraction and inhibited enzyme secretion by 30%. Atropine caused a small reduction in gallbladder volumes, but essentially blocked postprandial enzyme secretion. The results indicate that CCK is the major regulator of gallbladder contraction with the cholinergic system modulating the response, while the exocrine pancreas is crucially dependent on a cholinergic background with CCK modulating the secretory response.
Similar articles
-
Interaction of the cholinergic system and cholecystokinin in the regulation of endogenous and exogenous stimulation of pancreatic secretion in humans.Gastroenterology. 1991 Feb;100(2):537-43. doi: 10.1016/0016-5085(91)90227-c. Gastroenterology. 1991. PMID: 1702077
-
Role of CCK in regulation of pancreaticobiliary functions and GI motility in humans: effects of loxiglumide.Am J Physiol. 1991 Feb;260(2 Pt 1):G197-206. doi: 10.1152/ajpgi.1991.260.2.G197. Am J Physiol. 1991. PMID: 1996640
-
Comparison of loxiglumide, a cholecystokinin receptor antagonist, and atropine on hormonal and meal-stimulated pancreatic secretion in man.Scand J Gastroenterol. 1990 Jul;25(7):731-8. doi: 10.3109/00365529008997600. Scand J Gastroenterol. 1990. PMID: 2396088
-
Effects of CCK on pancreatic function and morphology.Ann N Y Acad Sci. 1994 Mar 23;713:180-98. doi: 10.1111/j.1749-6632.1994.tb44065.x. Ann N Y Acad Sci. 1994. PMID: 8185159 Review.
-
Cholecystokinin in the control of gastric acid and plasma gastrin and somatostatin secretion in healthy subjects and duodenal ulcer patients before and after eradication of Helicobacter pylori.J Physiol Pharmacol. 1994 Dec;45(4 Suppl 1):3-66. J Physiol Pharmacol. 1994. PMID: 7787215 Review.
Cited by
-
Expression of cholecystokinin-1 receptor is correlated with proteinuria in human diabetic nephropathy.Endocrine. 2012 Oct;42(2):329-34. doi: 10.1007/s12020-012-9630-2. Epub 2012 Mar 7. Endocrine. 2012. PMID: 22396142
-
Unexpected relationship between plasma protein binding and the pharmacodynamics of 2-NAP, a CCK1-receptor antagonist.Br J Clin Pharmacol. 2007 May;63(5):618-22. doi: 10.1111/j.1365-2125.2006.02789.x. Epub 2006 Oct 17. Br J Clin Pharmacol. 2007. PMID: 17052250 Free PMC article. Clinical Trial.
-
Pharmacological profile of TP-680, a new cholecystokininA receptor antagonist.Br J Pharmacol. 1996 Apr;117(7):1558-64. doi: 10.1111/j.1476-5381.1996.tb15321.x. Br J Pharmacol. 1996. PMID: 8730754 Free PMC article.
-
Increased gall bladder volume in primary sclerosing cholangitis.Gut. 1996 Oct;39(4):594-9. doi: 10.1136/gut.39.4.594. Gut. 1996. PMID: 8944571 Free PMC article.
-
Direct measurement of pancreatic enzymes: a comparison of secretagogues.Dig Dis Sci. 2002 Oct;47(10):2211-6. doi: 10.1023/a:1020127025489. Dig Dis Sci. 2002. PMID: 12395893 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources